These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12206969)

  • 1. Fluoroquinolone resistance among Gram-positive cocci.
    Hooper DC
    Lancet Infect Dis; 2002 Sep; 2(9):530-8. PubMed ID: 12206969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
    Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
    J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong.
    Morrissey I; Farrell DJ; Bakker S; Buckridge S; Felmingham D
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1433-5. PubMed ID: 12654686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
    Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
    Harding I; Simpson I
    J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of and resistance to quinolones.
    Bearden DT; Danziger LH
    Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
    Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
    Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
    Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
    Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
    Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
    Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
    J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
    Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
    Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
    Christiansen KJ; Bell JM; Turnidge JD; Jones RN
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2049-55. PubMed ID: 15155198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies.
    Vickers AA; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2007 Aug; 60(2):269-73. PubMed ID: 17556355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
    Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
    Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.